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Preeclampsia, affecting 5–8% of pregnancies, is the main
cause of fetal–maternal mortality and morbidity. The
differential diagnosis with chronic kidney disease (CKD) is a
challenge owing to the overlapping clinical features. No
biomarker has been found to discriminate between the two
conditions. Here, we tested whether maternal serum levels of
placental growth factor (PlGF) and soluble FMS-like tyrosine
kinase-1 (sFlt-1), markers of preeclampsia, could be used to
discriminate between 34 patients with preeclampsia,
23 patients with CKD during pregnancy, and 38 healthy
pregnant women. Serum levels of PlGF and sFlt-1 were
determined during the third trimester by commercially
available immunoassays. In preeclampsia, sFlt-1 levels were
significantly increased in comparison with that in CKD and in
the control women. Serum levels of PlGF in preeclampsia
were significantly decreased relative to both controls and
patients with CKD. The sFlt-1 to PlGF ratio was significantly
increased in preeclampsia (median 436) compared with
controls (median 9.4) and CKD (median 4.0). No differences
were found between controls and patients with CKD. Thus,
our study suggests that it is possible to discriminate between
preeclampsia and CKD during pregnancy by determining
maternal serum levels of sFlt-1 and PlGF and their ratio.
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The complex relationship between kidney and placenta has
been known since the start of modern medicine. The
importance of a differential diagnosis between preexisting
kidney disease, eventually exacerbated by pregnancy, and
pregnancy complicated by proteinuria and hypertension was
underlined over a century ago.1 Both diseases are frequent
and increasing in frequency. Preeclampsia (PE) complicates
5–8% of all pregnancies,2 whereas chronic kidney disease
(CKD) affects 2–3% of women in childbearing age.1,3,4
The differential diagnosis between PE and CKD is still a
challenge. Both diseases were recently redefined, widening the
definitions and pursuing an earlier diagnosis.3,4 The frequent
lack of historical data limits the potentials of a differential
diagnosis. Furthermore, glomerulonephritis, as well as systemic
immunologic diseases, may appear, relapse, or worsen in
pregnancy; some glomerular diseases, such as IgA nephropa-
thy, may cause proteinuria or hypertension in pregnancy.5–8
The discrimination between PE and CKD has important
consequences. The clinical course of PE is often more
aggressive and stormy, and the indications in severe cases are
toward early delivery, whereas a wait-and-watch policy may
be more rewarding in CKD.2
Recent studies have underlined the association between PE
and end-stage kidney disease later in life.4,8 In particular,
Vikse et al.4 performed a cohort study on more than one
million women with one to three pregnancies and reported
that PE could be considered a clinical marker for an increased
risk of subsequent end-stage renal disease. This risk is
particularly high if PE results in the birth of a low-birth-
weight or preterm baby or if PE occurs in more than one
pregnancy.4 The role of undiagnosed CKD in the develop-
ment of ‘early PE’ has been a matter of discussion.4 In spite of
the great interest in this complex subject, no clinical criteria
or biomarker is currently available to support the differential
diagnosis between CKD and PE.
The etiopathogenesis of PE remains elusive. There is evidence
indicating that hypertension, proteinuria, and generalized
endothelial dysfunction are directly caused by an unbalanced
production of placental pro- and anti-angiogenic molecules.
In particular, soluble FMS-like tyrosine kinase-1 (sFlt-1) and
placental growth factor (PlGF) are believed to be pivotal in
PE pathophysiology.9,10 During normal placenta development,
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vascular endothelial growth factor and PlGF have a key role
in regulating trophoblast growth and differentiation, villous
angiogenesis, and remodeling of maternal spiral arteries.9,10
In PE, the placenta fails to properly invade and remodel
maternal uterine spiral arteries, leading to impaired perfusion,
hypoxia/ischemia, and oxidative placental stress.11–13 This
condition triggers the overactivation of hypoxia-inducible
factor 1a, a main factor in the cellular response to hypoxia.14
The hypoxia-inducible factor 1a target genes are pro-angio-
genic vascular endothelial growth factor and anti-angiogenic
sFlt-1, both overexpressed in PE.15–17 Indeed, abnormally
elevated concentrations of placental and circulating sFlt-1,
induced by hypoxia/oxidative stress, inhibit free vascular
endothelial growth factor and PlGF, thus causing, and/or
contributing to, the aberrant placental angiogenesis and
generalized endothelial dysfunction.15,17 Recently, it was
demonstrated that vascular endothelial growth factor specifi-
cally produced by the podocyte is required to maintain the
integrity of the glomerular filtration barrier.18
The identification of an sFlt-1/PlGF imbalance as a key
event in the pathogenesis of PE has led to new diagnostic and
therapeutic perspectives. Both factors are detectable in the
maternal circulation at least 5 weeks before the onset of
clinical PE, and several groups are working to establish
reference values applicable in clinical practice.17,19,20 In normal
pregnancies, maternal serum levels of sFlt-1 continuously
increase during pregnancy, whereas PlGF levels increase until
the middle of the third trimester and then decrease at the end
of pregnancy.20
From the pathophysiological point of view, we can
expect CKD to behave differently from PE, as CKD patients
should have a normal early phase of placental implantation.
According to this hypothesis, the sFlt-1/PlGF balance should
be normal in pregnant CKD patients in spite of proteinuria
or hypertension, thus differentiating between these two
conditions.
The aim of this study was to test this hypothesis in a
homogeneously followed sample of PE and CKD patients.
The results could be of great use in supporting the clinical
management of patients with proteinuria and hypertension
in pregnancy.
RESULTS
Clinical features of the study population
The study population data are summarized in Table 1. There
were no clinically relevant differences in age at the start of
pregnancy or prevalence of primiparous mothers. Protein-
uria, by definition absent in the controls, was significantly
higher in PE than in CKD. The clinical outcomes differed in
both groups with respect to controls and were more severe in
PE patients (Table 1).
sFlt-1 and PlGF levels and sFlt-1/PlGF ratio in PE, CKD,
and controls
Serum levels of sFlt-1 and PlGF, and their ratio, were
significantly different between PE and controls and between
PE and CKD, whereas no difference was found between CKD
and controls (Table 1, Figure 1a). sFlt-1 protein levels were
significantly increased in PE relative to both CKD and
controls (5.12- and 4.25-fold higher, respectively, Po0.0001)
(Figure 1a, left panel; Table 1). PlGF serum levels were
significantly decreased in PE relative to both CKD and
controls (17.4- and 12.5-fold lower, respectively, Po0.0001)
(Figure 1a, middle panel; Table 1). Receiver operating
characteristic curve analysis showed that the sFlt-1 concen-
tration cutoff value to discriminate between PE and CKD
patients was 7715 pg/ml (sensitivity 97%, specificity 96%),
while for PlGF it was 88.15 pg/ml (sensitivity 90%, specificity
100%).
The sFlt-1/PlGF ratio was significantly increased in PE
relative to CKD and controls (about 25-fold higher in both
cases, Po0.0001), but there was no significant difference
between CKD and controls (Figure 1a, right panel; Table 1).
Also noteworthy was the lack of overlap of the ranges of the
ratio in PE versus CKD and controls (Figure 1b). The sFlt-1/
PlGF ratio cutoff value to discriminate between PE and CKD
patients was 148.75 (sensitivity 100%, specificity 100%), as
determined by receiver operating characteristic curve analy-
sis. Nevertheless, as there is no overlap of the ranges, any
value between 136.59 and 160.9 could be equally used to
discriminate the two pathologies.
DISCUSSION
PE and CKD have overlapping clinical features, characterized
by hypertension and proteinuria, which often render a differ-
ential diagnosis impossible. Therefore, the main result of our
study was to confirm that PE and CKD differently affect
pregnancy and may be differentiated by specific circulating
biomarkers (Table 1, Figure 1a and b). We were able to
distinguish between PE and CKD by measuring the ratio of
circulating sfFlt-1/PlGF levels, whose value seems to discri-
minate these conditions without any overlap. Therefore, any
value of sFlt-1/PlGF ratio between 136.59 and 160.9 could be
equally used to discriminate the two pathologies. A cutoff
value of 148.75 (rounded to 150) can be suggested.
Thus, our study suggests that the pathogenesis of
pregnancy-related problems is different in CKD and PE. In
the former, it is linked to the maternal disease, in which the
markers of placentation are no different from those of
normal pregnancies. In PE, the pathogenesis is linked to a
primary defect in placentation. It could be argued that sFlt-1
is a common anti-angiogenic marker, expected to be increased
in both pathological conditions. However, we can speculate
that in CKD the vascular damage is limited to the kidney,
whereas the hypoxic/ischemic PE placenta releases anti-
angiogenic and proinflammatory molecules into the maternal
circulation, causing generalized endothelial damage.17
Recent clinical–experimental studies have related elevated
circulating levels of sFlt-1 to anti-neutrophil cytoplasmic
antibody–associated vasculitis.21 In particular, sFlt-1 levels
during the acute phase were correlated with the degree of
proteinuria.21 As observed by Stillman and Karumachi,22
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Table 1 | Clinical characteristics of the study population
PE (34)a CKD (23) Controls (38) P-values
Age at start of pregnancy 32.5±4.46 29.5±5.87 31.5±5.37 P¼ 0.0327
P1¼NS
P2¼NS
Primiparous (%) 24/33 (72.7%) 12 (52.2%) 22 (57.9%) P¼NS
P1¼NS
P2¼NS
Proteinuria at test (g/day) 2.62 0.75 (Absent) P¼ 0.0002
(Range) (0.45–18.36) (0.3–6.83)
(25th–75th Percentiles) (1.07–6.60) (0.3–1.3)
Week at test 30.5±3.25 29.8±6.06 34.5±5.12 P¼NS
P1¼ 0.0002
P2¼ 0.0020
Week of delivery 30.8±3.15 36.1±2.82 39.1±1.88 Po0.0001
P1o0.0001
P2o0.0001
Preterm (o37 weeks) 33 (97.1%) 10 (43.5%) 3 (7.9%) Po0.0001
P1o0.0001
P2¼ 0.0030
Early preterm (o34 weeks) 27 (79.4%) 4 (17.4%) 1 (2.6%) Po0.0001
P1o0.0001
P2¼NS
Cesarean section (%) 32 (94.1%) 11 (47.8%) 10 (26.3%) P¼ 0.0002
P1o0.0001
P2¼NS
Need for NICU 27/33 (81.8%) 4/22 (18.2%) 3 (7.9%) Po0.0001
P1o0.0001
P2¼NS
Birth weight (g) 1271±531.9 2531.2±633.17 3212.4±486.35 Po0.0001
P1o0.0001
P2o0.0001
SGA babies o10th percentile (o5th percentile) 13/27–48.1% 5–21.7% 6–15.8% P¼NS P1¼ 0.0047
(3/27–11.1%)b (3–13%) (3–7.9%) P2¼NS
(P¼NS P1¼NS P2¼NS)
Gestational week at test 30.6±3.25 29.8±6.06 34.5±5.12 P¼NS
P1¼ 0.0003
P2¼ 0.0020
sFlt-1 (pg/ml) 13519.5 1988 2499 Po0.0001
(Range) (6059–34398) (692–11172) (823–14833) P1o0.0001
(25th–75th percentiles) (10507–18786) (1402–2978) (1737–4070) P2¼NS
PlGF (pg/ml) 32.6 426.5 279.3 Po0.0001
(Range) (11–86.9) (55.9–2632) (43.5–1262) P1o0.0001
(25th–75th Percentiles) (19–44) (106–626) (142–578) P2¼NS
sFlt-1/PlGF 435.79 4.003 9.36 Po0.0001
(Range) (160.90–1153.53) (0.51–136.59) (1.38–126.83) P1o0.0001
(25th–75th Percentiles) (276–703) (2.6–20.9) (3.1–29.7) P2¼NS
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate; NICU, neonatal intensive care unit; NS, not significant; PE, preeclampsia; PlGF, placental growth
factor; sFlt-1, soluble FMS-like tyrosine kinase-1; SGA, small for gestational age.
P¼ PE versus CKD; P1¼ PE versus controls; P2¼CKD versus controls.
Only CKD patients who presented with both hypertension and proteinuria were selected for this study. The kidney diseases were as follows: glomerular disease (17.4%),
interstitial disease (30.5%), pyelonephritis (13%), polycystic kidney disease (4.3%), kidney transplant (13%), isolated urinary abnormalities (4.3%), and solitary kidney (17.4%).
Kidney function was normal (GFR490ml/min) in all controls and PE patients; all but three patients in the CKD group were in stage 1 CKD; three patients were in
stage 2 CKD.
aOne case excluded (intrauterine death).
bSGA babies: only cases with gestational age X28 weeks were considered (no reference data below this term).
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these data emphasize the pivotal role of angiogenic and anti-
angiogenic molecules in maintaining blood vessel homeo-
stasis. Indeed, the investigation of circulating markers of
disrupted angiogenesis in PE may offer some insights also for
diseases characterized by severe endothelial dysfunction, such
as vasculitis or severe CKD.
The timely identification of CKD patients should lead to
better management of pregnancy, as strict clinical control
may allow the fetuses of CKD patients to reach a higher
gestational age, whereas in PE a stormy course could more
easily be expected and timely delivery is indicated as the only
‘cure’.2,23 After pregnancy, the identification of CKD patients
may allow the planning of specific diagnostic and treatment
pathways for patients who could otherwise lose this unique
occasion for a cure.23
The strength of this paper is the proposal of the first
biomarkers able to differentiate PE and CKD in pregnancy in
a highly significant way, particularly via the sFlt-1/PlGF ratio
(Table 1, Figure 1a and b). The main limit of this paper,
partly shared by preliminary reports, is the small number of
cases enrolled in the study. However, our results for PE and
control patients are in line with those obtained in a larger
population currently taken as a reference for the commercial
kits used.20 Furthermore, we selected only cases with a full-blown
PE picture and with CKD presenting with hypertension and
proteinuria; broader recruitment, also including CKD patients
without proteinuria and hypertension and patients with
pregnancy-induced hypertension, is advisable to provide
better insights into these complex and often overlapping
conditions. Both limits have been taken into account in the
planning of a larger prospective study, to be extended on a
multicenter scale, aimed at following larger numbers of both
CKD and PE patients and at performing serial tests until
delivery and also after delivery.
In conclusion, the results of the present study suggest that
sFlt-1, PlGF, and, above all, their ratio are the first biomarkers
thus far to differentiate between PE and CKD, a crucial issue
to allow the best clinical management of the pregnancies and
to allow timely diagnosis of CKD. Larger multicenter studies
are needed to best explore the potentials of these tests, which
represent the first successful attempt to perform a rapid
noninvasive differential diagnosis between these two emerg-
ing diseases.
MATERIALS AND METHODS
Study population
The study was conducted at the Maternal and Fetal Medicine Unit of
O.I.R.M-Sant’Anna Hospital, University of Turin (Turin, Italy).
Patients were recruited and blood samples were obtained after
informed consent in accordance with the ethics guidelines of
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Figure 1 | sFlt-1 and placental growth factor (PlGF) levels and sFlt-1/PlGF ratio in preeclampsia (PE), chronic kidney disease (CKD),
and control patients. (a) sFlt-1 (left panel), PlGF (middle panel), and sFlt-1/PlGF ratio relative to fold increases in PE versus CKD and control
(Ctrl) patients as assessed by the Elecsys methodology. Significance was considered as Po0.05. (b) Scatterplot of calculated sFlt-1/PlGF ratio.
Black squares, PE patients; gray squares, CKD patients; white circles, control patients. *Po0.001.
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O.I.R.M.-Sant’Anna Hospital. The study was approved by the Ethics
Committee of the Sant’Anna Hospital (no. 335; protocol 11551/
c28.2; 4/3/2011).
In total, 34 PE patients, 23 pregnant woman with CKD, and 38
controls (healthy women with uncomplicated pregnancy) were enrolled.
PE was defined as hypertension with systolic blood pressure
X140mmHg or diastolic blood pressureX90mmHg accompanied
by proteinuria X300mg/24 h after 20 weeks of gestational age in a
previously normotensive woman.2 CKD was defined as ‘every anomaly
of blood and urine composition, or imaging or pathological data,
lasting for at least 3 months or with a glomerular filtration rate
below 60ml/min for the same time period’.3,23 Glomerular filtration
rate was calculated by the Cockroft–Gault and MDRD formulae on
data obtained within 3 months before conception. When this was
not available, serum creatinine measured at first control during
pregnancy was used.23 For the sake of this study, only patients with
known CKD who presented both hypertension and proteinuria of
at least 300mg/day, i.e., a clinical and laboratory picture superi-
mposable on PE, were selected. Controls had normal pregnancies
with no signs of PE, CKD, or other maternal or fetal diseases.
Exclusion criteria were twin pregnancies, congenital malformations,
chromosomal anomalies, or maternal diseases other than CKD.
The following data were considered for CKD and PE: protein-
uria, serum creatinine, glomerular filtration rate, total serum
albumin, blood pressure, and antihypertensive therapy, age, parity,
race, week of testing, educational level, body mass index, gestational
age at delivery, type of delivery, clinical complications in the mother,
fetal weight, percentile with respect to the Italian birth weight
references, Apgar index, sex, admission to the neonatal intensive
care unit, and outcome.
sFlt-1 and PlGF assays
A volume of 2ml of venous blood was collected from each patient
and control using serological vials without anticoagulant and gel.
Serum was obtained by centrifugation at 3000 r.p.m. at 4 1C for
20min within 3h from collection and stored at  80 1C until testing.
All samples were analyzed contemporaneously. Serum levels of sFlt-1
and PlGF were determined in parallel by specific commercially
available electrochemoluminescence immunoassays (Elecsys, Roche,
Penzberg, Germany) using a Cobas-e-411 immunoanalyzer follow-
ing the manufacturer’s instructions and as previously described by
Verlohren et al.20 Normal controls were compared with the reference
data supplied by the manufacturer and Verlohren’s data.20 The values of
sFlt-1 in the serum of our control pregnancies (3270±405 pg/ml)
were comparable to those reported by Verlohren et al.20 (2641±
100.5 pg/ml).
Statistical analysis
A descriptive analysis was performed as appropriate (mean and
standard deviation for parametric and median and range for non-
parametric data). Comparison among groups was performed by
analysis of variance. Bonferroni’s test was used for post-hoc
comparisons between two groups of parametric data, while
Kruskal–Wallis test was used for nonparametric data and chi-square
test for frequencies. Receiver operating characteristic curves were
used to determine cutoff values for sFlt-1 and PlGF measurements
and their ratio. Significance was set at o0.05.
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